Selective Retina Therapy With 'R:GEN' in Patients With Central Serous Chorioretinopathy

Inclusion Criteria: 1. Male and female adult patients aged 19 or over and less than 55 2. Patients who have had clinical symptoms of central serous chorioretinopathy over 3 months. 3. Patients whose best corrected visual acuity (BCVA) is at least 20/200 based on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart (BCVA based on the ETDRS chart will be converted into logMAR) 4. Patients with Sub-Retinal Fluid (SRF) that has been going into the fovea continuously 5. Patients with ≥1 \~ ≤ 3 active leakage sites in Fundus Fluorescein Angiography (FA) 6. Patients who are of child-bearing potential and have agreed to use a medically acceptable contraceptive method during the study period ☞Medically acceptable contraceptive method: Condom, oral contraceptive pills that have been continued for more than three months, contraceptive injection or implants or intrauterine contraceptive device 7. Patients who voluntarily agree to participate in this study, and are willing to and able to follow the protocol. Exclusion Criteria: 1. Patients with other retinal diseases such as choroidal neovascularization, polypoidal choroidal vasculopathy. 2. Patients with the conditions that make laser therapy difficult such as cataract or vitreous cloudiness. 3. Patients who have atrophy (diameter: ≥1000㎛) in the retinal pigment epithelium including the fovea. 4. Patients who had undergone laser or photodynamic therapy for central serous chorioretinopathy prior to the study participation. 5. Patients who have received steroid treatment (periocular, subtenon, intraocular) within the last one year 6. Patients who have received intraocular injection of anti-Vascular Endothelial Growth Factor (anti-VEGF) agent within the last six months. 7. Patients who have undergone ophthalmological surgery such as intraocular surgery or vitrectomy within the last six months. 8. Patients who have taken medication for central serous chorioretinopathy such as acetazolamide, spironolactone, and kalidinogenase \[within the last two months\]. 9. Patients who have a history of allergy to fluorescein used for FA and indocyanine green used for ICG angiography. 10. Female patients who are pregnant or breastfeeding. 11. Patients with systemic diseases such as Cushing's syndrome, inflammatory diseases, uncontrolled hypertension and diabetes, liver diseases, kidney diseases. 12. Patients who have pigment epithelial detachment that is directly related to the point of leakage with a diameter of more than 1000 μm. 13. Patients who are considered ineligible for this study according to the investigator's judgment.